Fadanafil

复达那非

Report date: 2026/05/09 20:00:18
NME

Base Information

Drug NameFadanafil
Drug Alias NameXZP-5849
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodiesterase 5A inhibitors
TargetsPhosphodiesterase 5A
Therapy Area/IndicationsErectile DysfunctionProstatic HyperplasiaPulmonary Arterial Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShandong Xuanzhu Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesLivzon Pharmaceutical Group IncShandong Xuanzhu Pharmaceutical Technology Co LtdXuanzhu (Shijiazhuang) Biotechnology Co Ltd +[4] 
Inactive CompaniesSihuan Pharmaceutical Holdings Group Ltd
Active IndicationsErectile DysfunctionProstatic HyperplasiaPulmonary Arterial Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A